OptimizeRx is a point-of-care engagement platform that spent the first half of the year proving it can drop low-quality volume and still print cash. The second-quarter print is not a growth story. It is a mix-shift story. A large managed-services program rolled off and a former ten-percent customer stayed dark. Revenue still fell by nearly a third, and yet adjusted earnings stayed close enough to the year-ago quarter that management left the full-year profit box unchanged.
The operating tension sits in the channel mix rather than in the cost line. Cost of revenue was cut by more than half as the company exited direct-to-consumer managed services, which lifted the implied gross margin into the mid-seventies for the quarter. That is the new economics management wants the market to treat as a baseline. The counterweight is net revenue retention at 90 percent, down from well above one hundred a year earlier, and average spend from the largest twenty manufacturers is shrinking. Mid-tier accounts are filling some of the hole, including one that entered the top ten, but they do not yet replace a darkened national brand.
Cash from operations in the first half was $8 million, almost matching last year on a smaller book. The company refinanced into a Fifth Third facility, prepaid principal, and still sits with more cash than term debt. Full-year revenue guidance stays in a band of $95 million. The open question is whether a back half that management still describes as older-cycle seasonality, with the fourth quarter carrying more than a third of the year, can refill a first half that already ran about $11 million behind.